Cargando…
Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease
INTRODUCTION: There is still a clear need for a widely available, inexpensive and reliable method to diagnose Alzheimer’s disease (AD) and monitor disease progression. Liquid chromatography–mass spectrometry (LC-MS) is a powerful analytic technique with a very high sensitivity and specificity. OBJEC...
Autores principales: | Marksteiner, Josef, Blasko, Imrich, Kemmler, Georg, Koal, Therese, Humpel, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725507/ https://www.ncbi.nlm.nih.gov/pubmed/29249916 http://dx.doi.org/10.1007/s11306-017-1297-5 |
Ejemplares similares
-
The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015) -
Use of Benzodiazepines in Alzheimer’s Disease: A Systematic Review of Literature
por: Defrancesco, Michaela, et al.
Publicado: (2015) -
Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy Subjects
por: Hochstrasser, Tanja, et al.
Publicado: (2011) -
Mechanisms Underlying the Anti-Aging and Anti-Tumor Effects of Lithocholic Bile Acid
por: Arlia-Ciommo, Anthony, et al.
Publicado: (2014) -
The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis
por: Lajczak‐McGinley, Natalia K., et al.
Publicado: (2020)